ArticleBlood advances2023
Survival after cancer-related venous thrombosis: the Scandinavian Thrombosis and Cancer Study.
Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis.European heart journal · 2026Pooled it
- Correlation between ALK+ non-small cell lung cancer targeted therapy and thrombosis: a systematic review and network meta-analysis.BMJ open · 2024Pooled it
- Clinically Relevant Bleeding in Individuals With Cancer: Insights From a Nationwide Cohort Study.American journal of hematology · 2026Article
- Role of Troponins in CardioOncology.Current treatment options in oncology · 2026Review
- Microfluidic Platforms for Modeling Cancer-Associated Thrombosis: Current Status and Future Directions.Research and practice in thrombosis and haemostasis · 2026Review
- GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality and hospitalization.The Journal of clinical endocrinology and metabolism · 2026Article
- A deep learning model to dynamically predict cancer-associated thromboembolism in large-scale healthcare systems.NPJ digital medicine · 2026Article
- Covalent organic framework-based electrochemical nanosensing: an emerging paradigm for early cancer diagnosis and longitudinal surveillance.Journal of nanobiotechnology · 2026Review
- Development and validation of an interpretable machine learning model for venous thromboembolism risk prediction in patients with lung cancer: a real-world study.Frontiers in medicine · 2026Article
- Article
- Cancer-associated venous thromboembolism and its impact on survival in the ONCOTHROMB12-01 cohort study.International journal of cardiology. Heart & vasculature · 2025Article
- Association of risk factors for venous thromboembolism and overall survival in lung cancer.Blood vessels, thrombosis & hemostasis · 2025Article
- Correlating Patient Symptoms and CT Morphology in AI-Detected Incidental Pulmonary Embolisms.Diagnostics (Basel, Switzerland) · 2025Article
- Mortality risk after cancer-related venous thromboembolism has decreased over the last three decades: the HUNT and Tromsø studies.Haematologica · 2025Article
- Clonal hematopoiesis in patients with cancer and its association with risk of thrombosis and prognosis of disease.Research and practice in thrombosis and haemostasis · 2025Article
- Safety and effectiveness of direct oral anticoagulants in fragile patients with venous thromboembolism: a retrospective cohort observational study.Annals of surgical treatment and research · 2025Article
- The Vienna CATScore for predicting cancer-associated venous thromboembolism: an external validation across multiple time points.ESMO open · 2025Article
- Magnitude of cancer-associated thrombosis in Africa: A systematic review and meta-analysis.iScience · 2025Article
- Occurrence and management of thrombosis recurrence and bleeding in low-molecular-weight heparin-treated patients with cancer-associated thrombosis: a French nationwide cohort study.Research and practice in thrombosis and haemostasis · 2025Article
- Risk assessment and prevention of cancer-associated venous thromboembolism in ambulatory patients with solid malignancies.Research and practice in thrombosis and haemostasis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with cancer have an increased risk of developing venous thromboembolism (VTE), and this combination is reported to result in poorer survival compared with cancer alone. This study aimed to investigate the impact of VTE on the survival of patients with cancer in a general population. The Scandinavian Thrombosis and Cancer (STAC) cohort, a population-based cohort including 144 952 participants without previous VTE or cancer, was used. During follow-up, cancer and VTE incidences were registered. "Cancer-related VTE" was defined as VTE diagnosed in patients with overt or occult cancer. The survival of participants without cancer and/or VTE ("disease-free") was compared with the survival of participants with cancer and cancer-related VTE. Cox regression models with cancer and VTE as time-varying exposures were performed to calculate hazard ratios for death. Subanalyses were performed across cancer types and stages and VTE type (deep vein thrombosis or pulmonary embolism). During follow-up (mean, 11.7 years), 14 621 participants developed cancer, and 2444 developed VTE, of which 1241 were cancer-related. The mortality rates (per 100 person years) for disease-free participants, VTE only, cancer only, and cancer-related VTE were 0.63, 5.0, 9.2, and 45.3, respectively. Compared with patients with cancer only, the risk of death for patients with cancer-related VTE was increased 3.4-fold. Within all cancer types, the occurrence of VTE increased the mortality risk 2.8- to 14.7-fold. In a general population, patients with cancer with VTE had a 3.4-fold higher mortality risk than patients with cancer without VTE, independent of cancer type.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.